Vitamin D3 for Life

Live Enlightened

Article

25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Full Study

Previous related page25-Hydroxycholecalciferol, the probable metabolically active form of vitamin D. Isolation, identification, and subcellular location: Full Evidence ReviewNext related page25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Study Summary
Study at a glance

Why do the usual vitamin D test and the active vitamin D test give different information?

This page explains why two vitamin D blood tests can give different information. The usual test measures 25-hydroxyvitamin D, the main form available in blood for conversion into active vitamin D. A different test measures 1,25-dihydroxyvitamin D, the active hormone. The body tightly controls how much active hormone it makes.

Who was studied to compare the two vitamin D blood tests?

The page brings together research reviews and a study of patient records. That study examined 319 people with low 25-hydroxyvitamin D levels. Researchers compared vitamin D measurements, calcium absorption and hormones involved in calcium control across four groups with different starting levels.

How did active vitamin D levels change when the usual vitamin D test was low?

Active hormone levels and calcium absorption were maintained in the three groups with less severe vitamin D shortage. Higher levels of parathyroid hormone helped maintain conversion to active vitamin D. In the group with 25-hydroxyvitamin D at 10 nmol/L or below, active hormone levels and calcium absorption were lower. This shows that the body’s ability to maintain active vitamin D has limits.

Can active vitamin D stay normal when the usual blood test shows low vitamin D?

A normal active-hormone result does not rule out low 25-hydroxyvitamin D. Kidney function, calcium-control hormones and pregnancy can affect active-hormone levels independently of the amount available for conversion. Neither blood test measures all vitamin D activity inside tissues. The tests answer different questions; one is not simply a better version of the other.

Read the full article below ↓

A blood result labelled “vitamin D” can refer to metabolites that occupy very different positions in vitamin D physiology. Circulating 25-hydroxyvitamin D, usually written 25(OH)D, is the main status marker and substrate pool. Circulating 1,25-dihydroxyvitamin D, or 1,25(OH)₂D, is the active endocrine hormone and is regulated much more tightly. The distinction matters because a low 25(OH)D concentration and a normal, or sometimes raised, 1,25(OH)₂D concentration can coexist without contradiction.

The two blood measurements answer different physiological questions

Vitamin D from skin or diet first undergoes 25-hydroxylation, principally in the liver, to form 25(OH)D. This metabolite is the major circulating pool and is present at concentrations that are far higher than those of 1,25(OH)₂D. Its production is influenced strongly by the amount of vitamin D substrate reaching the liver, so its circulating concentration carries useful information about recent and longer-term vitamin D availability. This is why 25(OH)D became the standard biochemical marker used when vitamin D status is actually being assessed.

The next activation step is different in character. The kidney converts 25(OH)D to 1,25(OH)₂D through CYP27B1, and the resulting hormone acts through the vitamin D receptor. Rather than simply tracking the size of the 25(OH)D pool, renal production is continuously adjusted to the body’s mineral and endocrine requirements. The pathway described in Vitamin D Activation therefore separates supply from regulated hormonal output.

Why 25(OH)D behaves more like a status marker

The evidence reviewed by Bikle and by Dirks and colleagues converges on a useful physiological contrast. Hepatic 25-hydroxylation is regulated less tightly than renal 1α-hydroxylation, while circulating 25(OH)D is comparatively abundant and stable enough to be measured routinely. These features do not make 25(OH)D a direct measure of vitamin D action. They make it a practical indicator of the circulating substrate reservoir from which endocrine and local vitamin D metabolism can proceed.

That distinction is important when interpreting What Vitamin D Levels Represent. A 25(OH)D result can help describe circulating vitamin D status, but it does not by itself report how much 1,25(OH)₂D a kidney is producing at that moment, how much active hormone is being generated inside individual tissues, or how strongly those tissues are responding through the vitamin D receptor. Status is an input to physiology, not a complete readout of physiology.

Why 1,25(OH)₂D is tightly controlled

Renal 1,25(OH)₂D production sits inside a feedback network linking calcium, phosphate, parathyroid hormone (PTH), fibroblast growth factor 23 (FGF23), CYP27B1 and CYP24A1. When calcium availability falls, increased PTH can stimulate renal CYP27B1 and favour production of 1,25(OH)₂D. FGF23 acts in the opposite direction by suppressing CYP27B1 and promoting the inactivation pathway through CYP24A1. The active hormone also participates in negative feedback on its own production and degradation.

The FGF23 literature adds a particularly clear demonstration that circulating active vitamin D is an actively governed endocrine output. Loss of normal FGF23 signalling in humans and experimental models can release renal 1α-hydroxylase from its normal restraint and produce inappropriately high 1,25(OH)₂D. The key point for biomarker interpretation is not the rare disorder itself, but what it exposes about ordinary physiology: 1,25(OH)₂D concentration is shaped by control signals, not simply by the amount of 25(OH)D present in blood.

Low 25(OH)D can coexist with maintained active hormone

Need and colleagues provided direct human evidence for this separation. They examined records from 3,661 patients and identified 319 in whom 25(OH)D was 40 nmol/L or lower and measurements of calcium absorption, PTH, vitamin D metabolites and bone-related markers were available. The patients were divided into four 25(OH)D bands: 0 to 10, 11 to 20, 21 to 30 and 31 to 40 nmol/L.

Across the three higher low-status groups, serum 1,25(OH)₂D and calcium absorption were maintained. The physiological explanation was secondary hyperparathyroidism: as substrate availability declined, PTH stimulation helped preserve conversion to the active hormone. This is exactly why a normal 1,25(OH)₂D result cannot be used as evidence that vitamin D stores or circulating status are necessarily adequate. The active hormone can be defended homeostatically while the substrate pool is already low.

The compensation has a limit in very severe depletion

The same study prevents the opposite oversimplification. In the group with 25(OH)D at 10 nmol/L or below, serum 1,25(OH)₂D, ionised calcium and calcium absorption were significantly lower, while PTH, alkaline phosphatase and a marker of bone turnover were higher. The authors concluded that at this extreme degree of substrate depletion, 25(OH)D could become insufficient to sustain normal 1,25(OH)₂D production despite secondary hyperparathyroidism.

This means the correct physiological statement is conditional. 1,25(OH)₂D is often maintained across ordinary low-25(OH)D states because of regulation, but it is not guaranteed to remain normal or elevated when substrate depletion becomes extreme, when renal activation is impaired, or when other parts of mineral metabolism are abnormal. Treating either “normal” or “low” active hormone as a universal rule would erase the very regulation that makes the two biomarkers different.

Circulating active hormone does not report all local vitamin D activation

Another limitation arises from compartmental biology. Many tissues can express CYP27B1 and generate 1,25(OH)₂D locally for intracrine or paracrine signalling. Dirks and colleagues note that locally produced 1,25(OH)₂D does not necessarily enter the systemic circulation in a way that materially changes the serum concentration. A blood measurement of 1,25(OH)₂D therefore mainly reflects the circulating endocrine pool, not the sum of active vitamin D production occurring inside every tissue.

This helps separate Vitamin D Status vs Vitamin D Effect from a simple two-number model. Neither 25(OH)D nor circulating 1,25(OH)₂D is a direct measurement of tissue-level biological effect. The first is primarily a status and substrate marker; the second is a regulated circulating hormone. Local enzyme expression, receptor availability, cell state and tissue-specific metabolism sit downstream of both.

Kidney and mineral physiology can change the relationship

Because the kidney is the major physiological source of circulating 1,25(OH)₂D, renal function is central to interpretation. Reduced renal activation capacity can lower active hormone even when 25(OH)D substrate is present. Conversely, disorders that alter PTH or FGF23 signalling can change 1,25(OH)₂D independently of nutritional status. These relationships are developed further in Vitamin D and Kidneys.

This is also why 1,25(OH)₂D has legitimate specialist uses. Reviews of clinical vitamin D testing describe value in selected disorders of 1α-hydroxylation, vitamin D receptor resistance, granulomatous or lymphoproliferative hypercalcaemia, and certain phosphate-wasting conditions. The mistake is not measuring 1,25(OH)₂D under any circumstances. The mistake is asking it to answer the different question of ordinary vitamin D status.

Measurement itself introduces another layer of interpretation

The biomarker distinction is physiological, but laboratory method matters as well. 25(OH)D is much more abundant than 1,25(OH)₂D, making the active hormone analytically more demanding to quantify. Both older and newer laboratory reviews describe method-specific limitations, while 25(OH)D assays can also differ in their handling of vitamin D₂, matrix effects and particular patient groups. The result is that “25 versus 1,25” is not the only testing question; the assay used and the clinical setting can influence confidence in the number.

These analytical issues do not reverse the physiological hierarchy. They explain why a status marker should not be treated as infallible, and why active-hormone measurement requires particular care. The broader constraints of blood-based interpretation are discussed in Free vs Total Vitamin D Explained, where binding and measured fractions add a separate dimension to what a circulating result means.

Physiological states can alter 1,25(OH)₂D without redefining vitamin D status

The active-hormone concentration also changes in physiological states that alter endocrine demand. Hollis highlighted pregnancy as an especially clear example: circulating 1,25(OH)₂D rises markedly, yet that rise is not evidence that the body has suddenly accumulated a proportionally larger vitamin D substrate pool. It reflects altered hormonal physiology. This is another reason the active metabolite cannot be interpreted on the same axis as 25(OH)D.

The broader lesson is that 1,25(OH)₂D is meaningful only in relation to the regulatory state that produced it. PTH, FGF23, kidney function, calcium and phosphate balance, pregnancy and disease can all change the endocrine demand for active hormone. A single concentration therefore sits downstream of multiple control signals. By comparison, 25(OH)D is closer to the supply side of the pathway, although it too is affected by binding, distribution, assay method and biological variation.

Why concentration and biological potency should not be confused

1,25(OH)₂D is biologically potent despite circulating at a far lower concentration than 25(OH)D. That is not an analytical curiosity; it reflects its role as a hormone. The body does not need a large circulating concentration of the active metabolite to generate receptor-mediated effects. Conversely, the much larger 25(OH)D pool should not be mistaken for the active signal itself. It functions as a stable reservoir from which regulated endocrine and local activation can occur.

This distinction helps explain why choosing a biomarker by the word “active” is physiologically backwards. The active form is valuable when the question concerns hormone production or regulation. The larger precursor is valuable when the question concerns circulating vitamin D status. The biological importance of a molecule and its suitability as a status biomarker are separate properties.

The evidence chain is stronger when the studies are read together

No single source establishes every part of this model. Need and colleagues show the human compensatory pattern and the point at which extreme substrate depletion can defeat it. Bikle and the FGF23 review explain why renal activation can move independently of hepatic substrate production. Dirks and colleagues connect that physiology to the laboratory question of which metabolite is informative in ordinary status assessment and which becomes useful in selected disorders. Hollis adds the practical measurement and clinical-interpretation boundary.

Taken together, the evidence supports a layered model rather than a one-number hierarchy. 25(OH)D and 1,25(OH)₂D are not competing tests in which one is simply “better.” They are measurements of different positions in the same regulated pathway. Their disagreement can itself be physiologically intelligible once substrate availability, endocrine control and organ function are separated.

The distinction also explains why a paired result should not be interpreted by asking which number is “better.” If the two concentrations appear discordant, the first task is to identify whether the pattern is expected from regulation. Low 25(OH)D with preserved 1,25(OH)₂D can reflect successful compensation; low active hormone with adequate substrate can direct attention toward renal activation or mineral-regulatory physiology. The value lies in matching each measurement to the process it represents.

What the evidence supports

  • 25(OH)D is the principal circulating marker used to assess vitamin D status because it reflects the larger substrate pool more directly than 1,25(OH)₂D.
  • Circulating 1,25(OH)₂D is a tightly regulated endocrine hormone whose concentration is shaped by PTH, FGF23, renal CYP27B1, degradation and feedback.
  • A low 25(OH)D concentration can coexist with maintained 1,25(OH)₂D, so a normal active-hormone result does not rule out low vitamin D status.
  • In very severe substrate depletion, compensation can fail and 1,25(OH)₂D can fall.
  • Circulating 1,25(OH)₂D does not measure all local tissue production or downstream vitamin D effect.
  • Neither biomarker should be interpreted without the clinical, renal, mineral and analytical context that determines what question it can answer.

How this fits the parent physiology page

The central testing distinction is summarised on Vitamin D Testing: 25-OH-D vs 1,25-OH₂-D. The evidence here supplies the physiological reason that the two numbers can diverge: one mainly describes circulating substrate status, while the other is an actively controlled hormonal output.

For a faster version of this evidence, see 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: Physiological Meaning and Regulation: Study Summary.

Primary evidence and source details

Vitamin D Metabolites and Calcium Absorption in Severe Vitamin D Deficiency. Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BEC. Journal of Bone and Mineral Research. 2008;23:1859 to 1863. DOI 10.1359/jbmr.080607.

Vitamin D Assays. Bikle DD. Frontiers of Hormone Research. 2018;50:14 to 30. PMID 29597233.

FGF23 and Vitamin D Metabolism. Latic N, Erben RG. JBMR Plus. 2021;5:e10558. PMID 34950827.

Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Hollis BW. Endocrinology and Metabolism Clinics of North America. 2010;39:271 to 286. PMID 20511051.

The When, What & How of Measuring Vitamin D Metabolism in Clinical Medicine. Dirks NF et al. Nutrients. 2018;10:482. PMID 29652819.

Related reading

Original sources

Source

Vitamin D Metabolites and Calcium Absorption in Severe Vitamin D Deficiency

Published in Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BEC. Journal of Bone and Mineral Research (2008).

Publication details

Vitamin D Metabolites and Calcium Absorption in Severe Vitamin D Deficiency. Need AG, O’Loughlin PD, Morris HA, Coates PS, Horowitz M, Nordin BEC. Journal of Bone and Mineral Research. 2008;23:1859 to 1863. DOI 10.1359/jbmr.080607.

Read more →
Source

Vitamin D Assays

Published in Bikle DD. Frontiers of Hormone Research (2018).

Publication details

Vitamin D Assays. Bikle DD. Frontiers of Hormone Research. 2018;50:14 to 30. PMID 29597233.

Read more →
Source

FGF23 and Vitamin D Metabolism

The purpose of this review is to highlight our current understanding of the molecular mechanisms underlying the regulation of vitamin D metabolism by FGF23, and to discuss the role of these mechanisms in physiology and pathophysiology.

Publication details

FGF23 and Vitamin D Metabolism. Latic N, Erben RG. JBMR Plus. 2021;5:e10558. PMID 34950827.

Read more →